Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study
Open Access
- 12 August 2016
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 16 (1) , 413
Abstract
Multi-drug resistant tuberculosis (MDR-TB) is a major public health problem especially in developing countries. World Health Organization (WHO) recommends use of Xpert MTB/RIF assay to simultaneously detecting Mycobacterium tuberculosis (MTB) and rifampicin (RIF) resistance. The primary objective of this study was to determine the frequency of MDR-TB in patients suspected to have drug resistance in Khyber Pakhtunkhwa. The frequency of probes for various rpoB gene mutations using Xpert MTB/RIF assay within 81 bp RRDR (Rifampicin Resistance Determining Region) was the secondary objective. A total of 2391 specimens, received at Programmatic Management of Drug Resistant TB (PMDT) Unit, Lady Reading Hospital (LRH) Peshawar, Pakistan, between October 2011 and December 2014, were analyzed by Xpert MTB/RIF test. MTB positive with rifampicin resistance were further analyzed to first line anti-mycobacterial drug susceptibility testing (DST) using middle brook 7H10 medium. The data was analyzed using statistical software; SPSS version 18. Out of 2391 specimens, 1408 (59 %) were found positive for MTB and among them, 408 (29 %) showed rifampicin-resistance with four different rpoB gene mutations within 81 bp RRDR. The frequency of various probes among RIF-resistant isolates was observed as: probe E, in 314 out of 408 isolates; B, 44 out of 408; A, 5 out of 408; D, 34 out of 408; and probe C was observed among 6 out of 408 RIF-resistant isolates. The probe A&B and E&D mutation combination was found in only 1 isolate in each case, while B&D mutation combination was detected among 3 out of 408 RIF-resistant isolates. Hence, it is concluded from our study on a selected population, 29 % of patients had MDR-TB. Probe E related mutations (also known as codon 531and 533) were the most common rpoB genetic mutation [314 (77 %)], acknowledged by Xpert MTB/RIF assay. Least mutation was detected within the sequence 511 (1.2 %).Keywords
This publication has 27 references indexed in Scilit:
- Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert®MTB/RIF in Kampala, Uganda: a retrospective studyBMC Infectious Diseases, 2014
- Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence settingBMC Microbiology, 2012
- Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence SettingAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Rapid Detection of Mycobacterium tuberculosis Complex and Rifampin Resistance in Smear-Negative Clinical Samples by Use of an Integrated Real-Time PCR MethodJournal of Clinical Microbiology, 2011
- Evaluation of the Analytical Performance of the Xpert MTB/RIF AssayJournal of Clinical Microbiology, 2010
- Performance Assessment of the GenoType MTBDR plus Test and DNA Sequencing in Detection of Multidrug-Resistant Mycobacterium tuberculosisJournal of Clinical Microbiology, 2009
- Prevalence of primary multidrug resistance to anti-tuberculosis drugs in Pakistan.2008
- Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosisJournal of Antimicrobial Chemotherapy, 1998
- The rapid diagnosis of isoniazid and rifampicin resistance in Mycobacterium tuberculosis -- a molecular storyJournal of Medical Microbiology, 1998
- Molecular genetic basis of antimicrobial agent resistance inMycobacterium tuberculosis: 1998 updateTubercle and Lung Disease, 1998